The stock of Clovis Oncology Inc (NASDAQ:CLVS) is a huge mover today! About 775,757 shares traded hands. Clovis Oncology Inc (NASDAQ:CLVS) has risen 68.34% since March 15, 2016 and is uptrending. It has outperformed by 62.86% the S&P500.
The move comes after 7 months positive chart setup for the $1.27 billion company. It was reported on Oct, 18 by Barchart.com. We have $45.47 PT which if reached, will make NASDAQ:CLVS worth $482.60M more.
Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on November, 3. They expect $-1.93 EPS, up 26.34% or $0.69 from last year’s $-2.62 per share. After $-2.07 actual EPS reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts -6.76% EPS growth.
Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage
Out of 8 analysts covering Clovis Oncology (NASDAQ:CLVS), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Clovis Oncology has been the topic of 23 analyst reports since September 10, 2015 according to StockzIntelligence Inc. The rating was maintained by Suntrust Robinson with “Buy” on Wednesday, August 24. The firm earned “Buy” rating on Friday, August 5 by Suntrust Robinson. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, February 26. The stock has “Buy” rating given by Stifel Nicolaus on Wednesday, September 21. The firm has “Neutral” rating given on Wednesday, August 24 by Mizuho. The firm has “Outperform” rating given on Wednesday, September 21 by Credit Suisse. SunTrust maintained the stock with “Buy” rating in Wednesday, August 24 report. The stock has “Buy” rating given by WallachBeth Capital on Thursday, September 10. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has “Neutral” rating given on Monday, November 16 by Mizuho. Mizuho maintained Clovis Oncology Inc (NASDAQ:CLVS) rating on Monday, January 25. Mizuho has “Neutral” rating and $23 price target.
According to Zacks Investment Research, “Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.13, from 0.87 in 2016Q1. The ratio improved, as 36 funds sold all Clovis Oncology Inc shares owned while 26 reduced positions. 18 funds bought stakes while 44 increased positions. They now own 36.50 million shares or 0.57% less from 36.71 million shares in 2016Q1.
Federated Investors Pa holds 11,957 shares or 0% of its portfolio. The New Jersey-based Blackrock Inv Management Limited Company has invested 0% in Clovis Oncology Inc (NASDAQ:CLVS). Antipodean Advisors Ltd Liability Company owns 523,000 shares or 4.34% of their US portfolio. Cypress Cap Management Limited Liability (Wy) holds 850 shares or 0% of its portfolio. Manufacturers Life Insur Company The, a Ontario – Canada-based fund reported 22,698 shares. Palo Alto Invsts last reported 3.94% of its portfolio in the stock. Renaissance Tech Llc last reported 307,200 shares in the company. State Board Of Administration Of Florida Retirement System holds 22,819 shares or 0% of its portfolio. Canada Pension Plan Board owns 32,700 shares or 0% of their US portfolio. California State Teachers Retirement Systems last reported 0% of its portfolio in the stock. Samlyn Ltd Liability Corporation last reported 0.22% of its portfolio in the stock. Sphera Funds Ltd holds 200,000 shares or 0.71% of its portfolio. Gemmer Asset Mgmt Lc accumulated 189 shares or 0% of the stock. Blackrock Fund, a California-based fund reported 1.27 million shares. Healthcor Mgmt Lp accumulated 1.98% or 2.65 million shares.
More news for Clovis Oncology Inc (NASDAQ:CLVS) were recently published by: Fool.com, which released: “Why Clovis Oncology Inc. Rose 52.7% in September” on October 10, 2016. Fool.com‘s article titled: “Why Clovis Oncology Shares Are Falling 14.5% Today” and published on October 07, 2016 is yet another important article.
CLVS Company Profile
Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Firm is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.